EVFM.OIDEvofem Biosciences, INC
10-Q: Evofem Biosciences Terminates Aditxt Merger, Faces Going Concern Doubt
Sentiment:
Quarterly Report
Evofem Biosciences reported Q3 2025 results, terminating its merger with Aditxt, facing substantial doubt about its ability to continue as a going concern, and navigating multiple debt defaults.
Delay expectedThe company failed to meet the terms of the TherapeuticsMD settlement agreement by July 2024, which required changing the name of PHEXX. The new name was approved by the FDA in April 2025, and re-branding plans are advancing.The proposed merger with Aditxt, Inc. was not consummated by the September 30, 2025 deadline and was subsequently terminated on October 20, 2025.
Capital raiseManagement's plans to meet cash flow needs include obtaining additional funding through non-dilutive or dilutive financings, collaborations, partnerships, license agreements, or other potential business combinations.The company is pursuing a fundraising round to provide critical capital for sales and marketing initiatives following the termination of the Aditxt merger.The Board approved the 2025 Equity Incentive Plan, authorizing up to 50 million shares, subject to stockholder approval, which could be used for future equity-based compensation.
Worse than expectedThe company faces substantial doubt about its ability to continue as a going concern, with insufficient liquidity for the next 12 months.Net product sales decreased by 13% for the nine months ended September 30, 2025, compared to the prior year.Common Stock was removed from OTCQB and now trades on OTCID due to failure to meet minimum bid price requirements.Multiple Notices of Default have been issued by Future Pak, LLC regarding the Baker Notes, claiming an Event of Default and accelerating repayment.Net cash used in operating activities increased for the nine months ended September 30, 2025.
Summary
- Net product sales decreased by 13% to $10.6 million for the nine months ended September 30, 2025, compared to $12.3 million in the prior year.
- Net loss improved significantly to $2.4 million for the nine months ended September 30, 2025, from $5.8 million in the prior year.
- Operating income was $27,000 for the nine months ended September 30, 2025, a substantial improvement from an operating loss of $6.7 million in the prior year.
- The merger agreement with Aditxt, Inc. was terminated on October 20, 2025, after stockholders did not approve the transaction.
- The company faces substantial doubt about its ability to continue as a going concern, with liquidity resources insufficient for the next 12 months.
- Common Stock was removed from OTCQB on April 23, 2025, and now trades on OTCID.
- A $1.9 million gain was recognized from the reversal of previously accrued Rush Royalty contingent liability due to patent expiration.
- Research and development expenses decreased by $5.0 million, primarily due to a $5.6 million reduction from negotiating trade payables and accrued liabilities.
- Multiple Notices of Default have been issued by Future Pak, LLC regarding the Baker Notes, which the company intends to vigorously contest.
- The Adjuvant Notes maturity date was extended to six months after October 13, 2025, or earlier upon certain events.
Sentiment
Score: 3
Explanation: While there are some operational improvements and strategic initiatives, the termination of the merger, significant going concern doubt, and ongoing debt defaults create a highly precarious financial situation. The decrease in net product sales for the nine-month period further dampens sentiment, despite an improved net loss driven by one-time accounting gains and expense reductions.
Positives
- Net loss significantly improved to $2.4 million for the nine months ended September 30, 2025, from $5.8 million in the prior year.
- Achieved operating income of $27,000 for the nine months ended September 30, 2025, compared to an operating loss of $6.7 million in the prior year.
- Recognized a $1.9 million gain from the reversal of previously accrued Rush Royalty contingent liability due to patent expiration.
- Research and development expenses decreased by $5.0 million, largely due to a $5.6 million reduction from negotiating trade payables and accrued liabilities.
- PHEXX net sales increased by 10% for the three months ended September 30, 2025, reflecting a full quarter of SOLOSEC and increased PHEXX WAC.
- Acquired global rights to SOLOSEC in July 2024, expanding the commercial portfolio.
- PHEXX approval rates consistently above 80% by payers, with 86% of commercial and Medicaid prescriptions approved as of May 2025.
- Expanded pharmacy network in California and the Northeast to improve patient access for PHEXX.
- Entered into a License and Supply Agreement with Windtree Therapeutics, Inc. for PHEXX manufacturing, expected to significantly reduce COGS.
- Investigator-led Phase 4 clinical trial for SOLOSEC in trichomoniasis is underway, funded by NIH.
- Investigator-led study of SOLOSEC in recurrent bacterial vaginosis showed promising efficacy for long-term symptom control.
- Licensed commercial rights for PHEXX and SOLOSEC in the MENA region to Pharma 1 Drug Store, LLC, with regulatory filings underway in UAE.
Negatives
- Net product sales decreased by 13% to $10.6 million for the nine months ended September 30, 2025, compared to $12.3 million in the prior year, primarily due to lower PHEXX sales volume.
- Working capital deficit of $70.3 million and an accumulated deficit of $900.2 million as of September 30, 2025.
- Net cash used in operating activities increased to $2.0 million for the nine months ended September 30, 2025, from $1.5 million in the prior year.
- Common Stock was removed from OTCQB on April 23, 2025, and now trades on OTCID due to failure to meet the minimum bid price requirement.
- Multiple Notices of Default have been issued by Future Pak, LLC regarding the Baker Notes, claiming an Event of Default and accelerating repayment of the outstanding principal balance, which could be up to two times the outstanding balance.
- The company failed to meet the terms of the TherapeuticsMD settlement agreement by July 2024, requiring a name change for PHEXX, and is working on resolution.
- Approximately 75% of trade payables were greater than 90 days past due as of September 30, 2025.
- The company has incurred operating losses and negative cash flows from operating activities since inception.
- The primary driver for the increase in the fair value of the Baker Notes in Q3 2025 was the company not retiring the notes by September 8, 2025, increasing the legally payable amount by approximately $2.8 million.
Risks
- Substantial doubt about the ability to continue as a going concern due to insufficient liquidity for the next 12 months.
- Disruptions in the commercialization of PHEXX or SOLOSEC and/or their supply chains could materially adversely affect business, results of operations, and financial condition.
- Risks and uncertainties related to changes in government operations, including a federal government shutdown, which could delay FDA reviews, disrupt supply chains, or affect healthcare reimbursement decisions.
- Potential legal action(s) against the company by Future Pak, LLC following the Notice of Default and cancellation of Forbearance Agreement, including the possibility of assets being taken.
- Inability to remediate material weaknesses in internal controls and procedures identified by management.
- Inability to obtain necessary approvals for corporate actions from stockholders, FINRA, Nasdaq, or other authorities.
- Inability to file Annual and Quarterly Reports on a timely basis.
- Inability to raise additional capital to fund operations if and as needed.
- Inability to achieve and sustain profitability.
- Inability to comply with debt arrangements, avoid future defaults, and pay amounts owed, including accelerated amounts.
- Potential for changes to current regulatory mandates requiring health insurance plans to cover FDA-approved contraceptive products without cost sharing.
- Inability to obtain or maintain third-party payer coverage and adequate reimbursement, and reliance on patients paying out-of-pocket.
- Inability to protect and defend intellectual property position and reliance on third-party licensors.
- Dependence on third parties for the manufacture of products.
- Inability to expand the organization to accommodate potential growth or retain and attract key personnel.
- The company may receive trade payable demand letters from other vendors that could lead to potential litigation, given 75% of trade payables are over 90 days past due.
- Uncertainty regarding the TherapeuticsMD dispute resolution, potentially incurring a loss of up to $2.3 million if Rush University pursues payment for accrued but unpaid royalties.
- Stockholder demands regarding alleged omissions of material information in proxy statements related to the terminated Aditxt merger.
Future Outlook
The company is pursuing a new path following the terminated Aditxt merger, including aiming to re-list its stock on the Nasdaq Capital Market or a comparable national market and complete a fundraising round to provide critical capital for sales and marketing initiatives designed to catalyze net sales growth over the next 18-24 months. It anticipates continued net losses for the foreseeable future and expects future equity-based compensation expense to increase following stockholder approval of the 2025 Equity Incentive Plan.
Management Comments
- We are now pursuing a new path, including aiming to re-list our stock on the Nasdaq Capital Market or a comparable national market and complete a fundraising round to provide critical capital for sales and marketing initiatives designed to catalyze our net sales growth over the next 18-24 months.
- We strongly disagree with the Designated Agent's claim that an Event of Default has occurred. We intend to vigorously contest any attempt by the Designated Agent and the Purchasers to exercise their default rights and remedies under the Baker Bros. SPA.
- Management believes that the condensed consolidated financial statements and related financial information included in this Quarterly Report on Form 10-Q fairly present in all material respects our financial condition, results of operations and cash flows as of the date presented, and for the periods ended on such dates, in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP).
- At this time, management does not expect any material adverse impact on our ongoing commercial operations [from a federal government shutdown], but we continue to monitor the situation.
Industry Context
Evofem Biosciences operates in the highly competitive women's sexual and reproductive health biopharmaceutical market. Its focus on non-hormonal contraception (PHEXX) and single-dose STI treatment (SOLOSEC) addresses specific unmet needs, particularly for women who cannot or prefer not to use hormonal methods. The company's strategy to expand PHEXX use in conjunction with GLP-1 medications for weight loss demonstrates an adaptive approach to emerging healthcare trends. International partnerships, such as with Pharma 1 in MENA, indicate a push for global market diversification, a common strategy for smaller biopharma firms seeking non-dilutive capital and broader reach. The ongoing clinical trials for SOLOSEC highlight continued investment in product efficacy and market differentiation within the STI treatment landscape.
Comparison to Industry Standards
- PHEXX is the first and only non-hormonal prescription contraceptive vaginal gel, differentiating it from hormonal contraceptive methods which are associated with side effects like depression, weight gain, headaches, loss of libido, mood swings, and irritability.
- SOLOSEC's single-dose oral antimicrobial agent for BV and trichomoniasis offers a simpler treatment option compared to multi-dose regimens like metronidazole (Flagyl 500 mg, administered twice daily for seven days), which often suffer from non-compliance (up to 50% for BV patients).
- Guidelines from the American College of Obstetricians and Gynecologists (ACOG) in 2020 and the U.S. Centers for Disease Control (CDC) in 2021 each include single dose SOLOSEC for the treatment of BV, indicating its alignment with current medical standards.
- A Phase 4 investigator-led clinical trial is comparing SOLOSEC 2g (one dose) versus metronidazole (multi-dose) for trichomoniasis, hypothesizing SOLOSEC will have a lower rate of repeat infections and be more cost-effective despite higher initial cost.
- An investigator-led study of SOLOSEC in recurrent BV demonstrated efficacy matching or potentially surpassing outcomes of current CDC-recommended suppressive treatments.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Board of Directors member (Aditxt) | Saundra Pelletier | NA | 2025-09-23 | Term expired. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Certificate of Designations Amendment | Amended and Restated Certificate of Designations of Series E-1 Convertible Preferred Stock (A&R E-1 Certificate of Designations) approved, increasing authorized shares from 2,300 to 10,000 for dividend payments and updating definitions. | 2025-09-30 | Increases flexibility for dividend payments in kind for Series E-1 Preferred Stock and updates definitions. |
| New Preferred Stock Series Creation | Certificate of Designations creating the Series G-1 Preferred Stock (G-1 Certificate of Designations) filed, authorizing a new series of convertible preferred stock. | 2025-08-22 | Introduces a new class of preferred stock with specific voting rights, conversion terms, and dividend entitlements, used for debt exchange. |
| Equity Incentive Plan Approval | Board of Directors approved the 2025 Equity Incentive Plan, authorizing up to 50,000,000 shares for issuance, subject to stockholder approval. | 2025-10-03 | Provides a framework for future equity compensation, potentially increasing dilution if approved and awards are granted. |
Legal Proceedings
- Trademark dispute with TherapeuticsMD, Inc. (Case No. 9:20-cv-82296) filed December 14, 2020, settled July 18, 2022. Company failed to meet settlement terms by July 2024 (changing PHEXX name). Working with TherapeuticsMD on resolution.
- Multiple letters received from purported stockholders demanding board action regarding alleged omissions of material information in proxy statements for the A&R Merger Agreement. Company believes demands are without merit and is working to resolve.
- Future Pak, LLC (assignee of Baker Notes) provided multiple Notices of Event of Default and Reservation of Rights (September 27, 2024, October 27, 2024, November 8, 2024) relating to the Baker Bros. SPA, claiming default and accelerating repayment. Company strongly disagrees and intends to vigorously contest.
Related Party Transactions
- Aditxt: The Amended and Restated Agreement and Plan of Merger with Aditxt, Inc. was terminated on October 20, 2025, after stockholders did not approve. On April 8, 2025, and June 26, 2025, the Company issued senior subordinated convertible notes (aggregate original principal $3.7 million) and warrants (242,257,742 shares) to Aditxt, generating approximately $2.4 million in net cash proceeds. Aditxt was granted a call option by Adjuvant to purchase Adjuvant Notes and Rights for $13.0 million, which expired on June 30, 2025. Aditxt holds all outstanding Series F-1 Shares, some issued in exchange for warrants/purchase rights, and 4,000 shares issued for $4.0 million as part of merger funding. Saundra Pelletier (CEO) served on Aditxt's Board of Directors from June 9, 2025, until September 23, 2025.
- Adjuvant: Adjuvant Global Health Technology Fund, L.P. holds unsecured convertible promissory notes. The company defaulted on these notes on September 30, 2023, but Adjuvant forbore the default in October 2023. The Adjuvant Third Amendment on October 13, 2025, extended the maturity date. On August 22, 2025, a portion of Adjuvant Notes (approximately $0.4 million) was exchanged for 365 shares of Series G-1 Preferred Stock. Adjuvant is considered a related party due to significant voting power from increased beneficial ownership limitation.
- Windtree Therapeutics, Inc.: On March 20, 2025, the Company entered into a License and Supply Agreement with Windtree for PHEXX manufacturing, expected to significantly reduce COGS. Saundra Pelletier (CEO) is also on the board of Windtree, making it a related party. No financial obligations have started yet under this agreement.
Stakeholder Impact
- Shareholders: Significant uncertainty due to going concern doubt, delisting from OTCQB, termination of the Aditxt merger, and potential dilution from future capital raises. The ongoing debt defaults and legal disputes could further negatively impact share value.
- Creditors (Baker Notes): Future Pak, LLC (assignee of Baker Notes) has issued multiple Notices of Default, accelerating repayment and potentially seeking two times the outstanding balance, which could lead to significant financial strain on the company.
- Creditors (Adjuvant Notes): The maturity date for Adjuvant Notes has been extended, providing some relief, but the company's overall financial health remains a concern.
- Employees: The company's precarious financial position and need for further spending reductions could impact employment stability.
- Customers: Continued commercialization of PHEXX and SOLOSEC, along with efforts to improve payer access and expand distribution, aim to benefit patients by providing access to women's health products.
- Suppliers: The company's practice of extending payment terms and having 75% of trade payables over 90 days past due indicates potential strain on supplier relationships and could lead to litigation.
Next Steps
- Pursue re-listing of common stock on the Nasdaq Capital Market or a comparable national market.
- Complete a fundraising round to provide critical capital for sales and marketing initiatives.
- Continue to generate recurring product revenue from PHEXX and SOLOSEC.
- Earn milestone payments by achieving certain regulatory milestones under the License and Supply Agreement with Pharma 1 for SOLOSEC.
- Restructure current payables.
- Obtain additional funding through non-dilutive or dilutive financings, collaborations, or partnerships.
- Vigorously contest any attempt by Future Pak, LLC to exercise default rights and remedies under the Baker Bros. SPA.
- Work with TherapeuticsMD on resolution of the settlement agreement failure.
- Advance re-branding plans and timeline for PHEXX.
- Seek stockholder approval for the 2025 Equity Incentive Plan at the annual meeting on November 26, 2025.
- Continue to monitor the potential impact of a federal government shutdown.
Key Dates
| Date | Description |
|---|---|
| 2020-04-23 | Company entered into Securities Purchase and Security Agreement with Baker Bros. Advisors LP. |
| 2020-04-24 | Baker Initial Closing for Baker Notes and Warrants. |
| 2020-06-09 | Baker Second Closing for Baker Notes and Warrants. |
| 2020-09-01 | Commercial launch of PHEXX in the U.S. |
| 2020-09-01 | Company entered into first amendment to Rush License Agreement. |
| 2020-10-14 | Company entered into Securities Purchase Agreement with Adjuvant Global Health Technology Fund, L.P. for Adjuvant Notes. |
| 2020-12-14 | Trademark dispute filed by TherapeuticsMD, Inc. against the Company. |
| 2021-01-01 | U.S. Medicaid population gained access to PHEXX. |
| 2021-11-20 | Company entered into first amendment to Baker Bros. Purchase Agreement. |
| 2022-03-21 | Company entered into second amendment to Baker Bros. Purchase Agreement. |
| 2022-04-04 | Company entered into first amendment to Adjuvant Purchase Agreement. |
| 2022-05-22 | PHEXX approved by FDA. |
| 2022-05-24 | May 2022 Common Stock Warrants became exercisable. |
| 2022-06-28 | June 2022 Baker Warrants became exercisable. |
| 2022-07-18 | Company settled lawsuit with TherapeuticsMD, Inc. |
| 2022-09-12 | Company was in default of Adjuvant Notes due to cross-default provision with Baker Notes. |
| 2022-09-15 | Company entered into third amendment to Baker Bros. Purchase Agreement and Secured Creditor Forbearance Agreement with Baker Purchasers. |
| 2022-09-15 | Company entered into Forbearance Agreement and second amendment to Adjuvant Purchase Agreement with Adjuvant Purchasers. |
| 2022-10-06 | PHEXX approved in Nigeria as Femidence. |
| 2022-10-31 | Company achieved Clinical Trial Milestone for EVOGUARD clinical trial. |
| 2022-12-19 | Company entered into First Amendment to the Forbearance Agreement with Baker Purchasers. |
| 2023-01-01 | Most insurers and PBMs must provide coverage for FDA-approved contraceptive products with $0 copay. |
| 2023-03-07 | Baker Bros. Advisors, LP provided Notice of Event of Default and Reservation of Rights relating to Baker Bros. Purchase Agreement. |
| 2023-06-30 | Company did not meet $100.0 million cumulative net sales threshold for PHEXX, resulting in default. |
| 2023-08-07 | Company filed Certificate of Designation of Series E-1 Convertible Preferred Stock. |
| 2023-09-08 | Company entered into Fourth Amendment to the Baker Bros. Purchase Agreement, curing existing defaults. |
| 2023-09-14 | Company amended its amended and restated certificate of incorporation to increase authorized Common Stock to 3,000,000,000 shares. |
| 2023-09-30 | Company was in default of Adjuvant Notes due to failure to meet cumulative net sales requirement. |
| 2023-10-01 | Adjuvant forbore default on Adjuvant Notes. |
| 2023-12-01 | Company entered into restructuring agreements with holders of Original SSNs, reissuing them as Exchanged SSNs with a maturity date of December 1, 2026. |
| 2023-12-11 | Baker Purchasers signed agreement to assign Baker Notes to Aditxt. |
| 2023-12-11 | Company filed Certificate of Designation of Series F-1 Convertible Preferred Stock. |
| 2023-12-21 | Warrants to purchase Common Stock exchanged for Series F-1 Shares. |
| 2024-02-26 | Baker Notes re-assigned back to Baker Purchasers from Aditxt. |
| 2024-04-23 | Common Stock removed from OTCQB and began trading on OTC Pink Current (OTCPK). |
| 2024-06-01 | Company entered into insurance premium finance agreement with First Insurance Funding. |
| 2024-06-01 | Company began participating in a 340B Group Purchasing Organization (GPO). |
| 2024-07-01 | Common Stock moved to and began trading on Over-the-Counter Integrated Disclosure (OTCID). |
| 2024-07-14 | Company acquired global rights to SOLOSEC. |
| 2024-07-14 | Company entered into Amended and Restated Agreement and Plan of Merger with Aditxt, Inc. |
| 2024-07-17 | Company licensed exclusive commercial rights for PHEXX in MENA to Pharma 1 Drug Store. |
| 2024-07-23 | Company consented to transfer of ownership of Baker Notes from Baker to Future Pak, LLC. |
| 2024-09-27 | Future Pak, LLC provided Notice of Event of Default and Reservation of Rights relating to Baker Bros. SPA. |
| 2024-10-27 | Future Pak, LLC sent amended and supplemental notice of default, terminating Forbearance Agreement. |
| 2024-11-01 | Relaunched SOLOSEC brand. |
| 2024-11-08 | Future Pak, LLC sent Third Amended Notice of Default, adding new claims. |
| 2025-01-06 | Company received notice from OTC Markets regarding non-compliance with minimum bid price requirement. |
| 2025-03-20 | Windtree Therapeutics, Inc. and the Company entered into a License and Supply Agreement. |
| 2025-04-08 | Company entered into securities purchase agreement with Aditxt for Aditxt April Note and Warrants. |
| 2025-04-10 | Aditxt, the Company, and Adjuvant entered into a Call Option Agreement for Adjuvant Notes and Rights. |
| 2025-04-22 | Company received notice from OTC Markets that it did not regain compliance with Minimum Bid Price Requirement. |
| 2025-04-24 | April 2020 Baker Warrants expired. |
| 2025-05-01 | Enrollment commenced in investigator-led Phase 4 clinical trial for SOLOSEC. |
| 2025-05-19 | Company licensed commercial rights to SOLOSEC in MENA to Pharma 1. |
| 2025-06-09 | June 2020 Baker Warrants expired. |
| 2025-06-26 | Company entered into securities purchase agreement with Aditxt for Aditxt June Note and Warrants. |
| 2025-06-30 | Call option for Aditxt to purchase Adjuvant Notes and Rights expired. |
| 2025-06-30 | Holders of a majority of issued and outstanding Series E-1 Shares approved the Amended and Restated Certificate of Designations of Series E-1 Convertible Preferred Stock. |
| 2025-06-30 | Company's Board of Directors approved the Amended and Restated Certificate of Designations of Series E-1 Convertible Preferred Stock. |
| 2025-07-01 | Common Stock began trading on Over-the-Counter Integrated Disclosure (OTCID). |
| 2025-08-22 | Company filed Certificate of Designations creating the Series G-1 Preferred Stock. |
| 2025-08-22 | Company entered into Exchange Agreements with certain SSN holders and Adjuvant for Series G-1 Shares. |
| 2025-09-08 | Repurchase price for Baker Notes increased from $14.0 million to $16.75 million (less Applicable Reductions). |
| 2025-09-23 | Saundra Pelletier's term on Aditxt's Board of Directors expired. |
| 2025-09-30 | Amended and Restated Certificate of Designations of Series E-1 Convertible Preferred Stock became effective. |
| 2025-10-03 | Board of Directors approved 2025 Equity Incentive Plan. |
| 2025-10-13 | Company and Adjuvant Purchasers entered into Adjuvant Third Amendment, extending maturity date. |
| 2025-10-20 | Company terminated A&R Merger Agreement with Aditxt after stockholders did not approve. |
| 2025-11-12 | Number of shares of Common Stock outstanding was 126,685,925. |
| 2025-11-26 | Annual meeting where stockholders will be asked to approve 2025 Equity Incentive Plan. |
Recommendation
strong sellThe company faces severe financial distress, evidenced by a substantial working capital deficit, accumulated deficit, and explicit 'going concern' doubt from management. The termination of the Aditxt merger removes a potential lifeline, and the company's stock has been delisted from OTCQB to OTCID. Multiple debt defaults, particularly with the Baker Notes, present immediate and significant financial liabilities that the company intends to contest, indicating prolonged legal battles. While there are some operational improvements and strategic initiatives (e.g., SOLOSEC acquisition, PHEXX rebrand, cost reductions from royalty reversal and payables negotiation), these are overshadowed by the critical liquidity issues and the high probability of further dilutive financing or asset liquidation. The overall risk profile is extremely high, making the stock a strong sell for investors.
Keywords
Evofem Biosciences, EVFM, PHEXX, SOLOSEC, Women's Health, Contraception, Bacterial Vaginosis, Trichomoniasis, Biopharmaceutical, SEC Filing, 10-Q, Going Concern, Debt Default, Merger Termination, OTC Markets, Financial Results
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.